Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksForterra Regulatory News (FORT)

Share Price Information for Forterra (FORT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 162.60
Bid: 161.00
Ask: 161.40
Change: 2.60 (1.63%)
Spread: 0.40 (0.248%)
Open: 160.00
High: 163.60
Low: 160.00
Prev. Close: 160.00
FORT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Post close half year trading update

11 Jul 2023 07:00

RNS Number : 5661F
Forterra plc
11 July 2023
 

11 July 2023

 

FORTERRA PLC

 

Post close half year trading update

 

In advance of the publication of our half year results on 27 July 2023 Forterra plc (the 'Group'), a leading UK manufacturer of essential clay and concrete building products, provides this trading update for the six-month period ending 30 June 2023 (the 'period').

 

Key points

 

· Resilient H1 results broadly in line with our expectations, delivered against a backdrop of challenging trading conditions

· We expect to report H1 revenues of approximately £183m, adjusted EBITDA of approximately £30m and adjusted PBT of approximately £18m

· Progressive signs of market improvement seen through May and June, although this improvement has been less pronounced than previously anticipated

· Considering the increasingly uncertain macroeconomic outlook we now expect to deliver full year 2023 EBITDA with a more balanced H1 / H2 split, reflecting only a modest improvement in trading conditions in H2

 

H1 results

 

· Subject to review by our auditors, we expect to report revenues for the period of approximately £183m, a decrease of 18% relative to the prior year (2022: £222.8m)

· We expect to report a resilient H1 result broadly in line with management expectations, with adjusted EBITDA of approximately £30m (2022: £46.1m) and adjusted PBT of approximately £18m (2022: £37.3m)

· Whilst market conditions remain competitive, our selling prices have remained firm and our cost base stable

· As planned, we have rebuilt our inventory, with stock levels increasing by approximately £30m in the period, leaving us well placed to deliver the service levels our customers expect

· We have maintained a strong and flexible balance sheet and expect to report a period end net debt before leases of approximately £50m (2022 year end: £5.9m) which is below 1x adjusted EBITDA on a LTM basis

 

Management actions

 

· In response to the challenging market conditions, and with our brick production capacity increasing with the opening of the new Desford factory, as previously announced, we have mothballed our Howley Park brick factory and implemented other production reductions which will reduce our fixed costs by around £10m on an annualised basis

· In addition, we are consulting with affected individuals on a restructuring of our commercial and support functions, aligning them to anticipated demand, which we expect to save approximately £3m annually

· The demand for our products in H2 will influence our production decisions. Having replenished our inventories in H1 we expect to limit our inventory growth in H2 and will continue to take appropriate action to ensure our output is aligned to demand

· Our strategy remains to maximise the ramp up of production at the new Desford factory, such that we can benefit from the market leading efficiencies it will offer once fully commissioned

 

Market backdrop and outlook

 

· UK brick industry despatches, as published by the Department of Business and Trade, were 31% adverse to the prior year in the five months to May 2023, with the month of May showing signs of an improving trend which is further evidenced by our own despatches for June, albeit this improvement is less pronounced than previously anticipated

· Encouragingly, imports of bricks to the UK have fallen significantly, decreasing 44% relative to 2022 in the four months to April, although they still remain high as a proportion of overall demand

· Although customer inventory reduction has been more prolonged than anticipated, we still expect this to ease in H2

· Demand for our products for the rest of the year remains subject to significant uncertainty with rising interest rates widely expected to adversely impact the demand for new homes for the foreseeable future

· Contrary to the wider macroeconomic backdrop, our precast flooring business, which can be regarded as a leading indicator for future brick and block demand is performing strongly, with despatches presently only 20% below prior year levels with current order intake running ahead of this

· As set out at the start of the year, our expectations for 2023 were based upon an underlying fall in full year market demand of 20% relative to 2022, with a slow start to the year followed by a meaningful recovery strengthening into H2 

· However, we are now assuming only a modest improvement in trading conditions, and therefore expect to deliver full year EBITDA with a more balanced H1 / H2 split

· The impacts of greater borrowing, inventory build, and rising interest rates are also expected to drive an increase in our financing costs

· Notwithstanding a weaker market in the short-term, looking further ahead, the Board remains confident that the Group remains well positioned to benefit from attractive market fundamentals of a shortage of UK housing supply, a shortfall of domestic brick production capacity and cross-party political support for increasing housing supply

 

This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) No 596/2014.

 

ENQUIRIES

 

Forterra plc +44 1604 707 600

Neil Ash, Chief Executive Officer

Ben Guyatt, Chief Financial Officer

 

FTI Consulting +44 203 727 1340

Richard Mountain / Nick Hasell

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFZGMNRGRGFZM
Date   Source Headline
15th Apr 20241:46 pmRNSAnnual Report & Accounts 2023 & Notice of AGM 2024
12th Apr 202412:09 pmRNSDirector/PDMR Shareholding
9th Apr 20244:22 pmRNSDirector/PDMR Shareholding
9th Apr 20244:19 pmRNSDirector/PDMR Shareholding
3rd Apr 20242:19 pmRNSDirector/PDMR Shareholding
27th Mar 20244:44 pmRNSDirector/PDMR Shareholding
25th Jan 202412:27 pmRNSDirector Declaration
24th Jan 20247:19 amRNSProgressive publish new research
24th Jan 20247:00 amRNS2023 Trading Update
23rd Jan 20247:00 amRNSHolding(s) in Company
8th Dec 20237:00 amRNSDirector Declaration
9th Nov 20237:00 amRNSAppointment of Joint Corporate Broker
20th Oct 20236:05 pmRNSDirector/PDMR Shareholding
11th Oct 20237:00 amRNSQ3 Trading Update
5th Oct 20235:04 pmRNSGrant of Options under 2023 SAYE Scheme
11th Sep 20237:00 amRNSHolding(s) in Company
1st Sep 20235:46 pmRNSHolding(s) in Company
23rd Aug 20233:59 pmRNSHolding(s) in Company
27th Jul 20237:00 amRNSSix months ended 30 June 2023
11th Jul 20237:00 amRNSPost close half year trading update
5th Jul 202312:39 pmRNSEmployee Benefit Trust Share Purchase
30th Jun 20231:51 pmRNSHolding(s) in Company
6th Jun 202312:57 pmRNSEmployee Benefit Trust Share Purchase
23rd May 20232:22 pmRNSAnnual General Meeting 2023 Results
18th May 202312:12 pmRNSProgressive publish new research
16th May 20237:00 amRNSPre-AGM trading update
5th May 20234:39 pmRNSDirector/PDMR Shareholding
4th May 20239:00 amRNSEmployee Benefit Trust Share Purchase
25th Apr 20237:00 amRNSNotification of Board Changes
11th Apr 20234:15 pmRNSPCA Shareholdings
4th Apr 20231:12 pmRNSEmployee Benefit Trust Share Purchase
3rd Apr 20232:03 pmRNSGrant under Performance Share Plan
29th Mar 202310:21 amRNSAnnual Report & Accounts 2022 & Notice of AGM 2023
16th Mar 20235:28 pmRNSGrant under Deferred Annual Bonus Plan
10th Mar 20239:18 amRNSProgressive publishes new research
9th Mar 20237:02 amRNSAppointment of Independent Non-Executive Director
9th Mar 20237:00 amRNSFull Year Results
3rd Mar 20232:18 pmRNSEmployee Benefit Trust Share Purchase
3rd Feb 202310:13 amRNSEmployee Benefit Trust Share Purchase
1st Feb 20238:18 amRNSDirector Declaration
25th Jan 20237:00 amRNSTrading Update
5th Jan 20233:12 pmRNSEmployee Benefit Trust Share Purchase
14th Dec 20225:10 pmRNSEmployee Benefit Trust Share Purchase
8th Dec 20227:00 amRNSHolding(s) in Company
2nd Dec 20224:10 pmRNSEmployee Benefit Trust Share Purchase
22nd Nov 20227:54 amRNSProgressive publishes new research
22nd Nov 20227:01 amRNSAppointment of Chief Executive Officer
22nd Nov 20227:00 amRNSTrading Update
4th Nov 20222:50 pmRNSEmployee Benefit Trust Share Purchase
2nd Nov 20228:45 amRNSDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.